Ionis to present at the Cowen Annual Health Care Conference
Ionis Pharmaceuticals (Nasdaq: IONS) will engage in a panel discussion focused on orphan neurological disease therapeutics at the upcoming Cowen 42nd Annual Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ionis Pharmaceuticals (Nasdaq: IONS) will engage in a panel discussion focused on orphan neurological disease therapeutics at the upcoming Cowen 42nd Annual Health Care Conference. The event is scheduled for 9:10 a.m. ET on March 7, 2022. Interested parties can access a live webcast on the company's Investors & Media section of their website, with a replay available for a limited time. Ionis boasts over 30 years in RNA-targeted therapy, including three marketed medicines and a robust late-stage pipeline that emphasizes neurological and cardiometabolic franchises.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was +2.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., March 1, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a panel discussion on orphan neurological disease therapeutics at the virtual Cowen 42nd Annual Health Care Conference at 9:10 a.m. ET on Monday, March 7, 2022.
A live webcast of this presentation can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com. A replay will be available for a limited time.
About Ionis Pharmaceuticals
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully-integrated biotechnology company.
To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-the-cowen-annual-health-care-conference-301492185.html
SOURCE Ionis Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.